From: A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis
Drug (REF.) | Changes in Brain Volume Loss | ||
---|---|---|---|
Year 0–1 | Year 1–2 | Year 0–2 | |
IFN-β-1a IM [33] | x | ✓ 55% reduction vs. placebo | x |
IFN-β-1a SC [34] | - | - | x |
- | - | - | |
x | ✓ | x | |
(Eur/Canadian GA trial) | 40% reduction vs. placebo (Eur/Canadian GA trial) | (Eur/Canadian GA trial) | |
8% reduction vs. sc IFN-β-1a (REGARD)+ | 22% reduction vs. sc IFN-β-1a (REGARD)+ | 13% reduction vs. IFN-β-1a (REGARD) | |
No sig. difference with GA +/− sc IFN-β-1b (BEYOND) | No sig. difference with GA +/−. sc IFN-β-1b (BEYOND) | No sig. difference with GA +/− sc IFN-β-1b (BEYOND | |
No sig. difference with GA +/− sc IFN-β-1a (COMBIRx) | No sig. difference with GA +/−. sc IFN-β-1a (COMBIRx) | No sig. difference with GA +/− sc IFN-β-1a (COMBIRx) | |
✓ | x (AFFIRM) | ||
40% increase vs. placebo (AFFIRM) | 44% reduction vs. placebo (AFFIRM) | ||
19% increase vs. placebo (SENTINEL) | x 23% reduction with Natalizumab+ IM IFN-β-1a vs. IM IFN-β-1a + placebo (SENTINEL) | x (SENTINEL) | |
Teriflunomide [42] | 37% reduction vs. placebo (TEMSO) | 31% reduction vs. placebo (TEMSO)- | X |
- | 21% reduction vs. placebo (DEFINE) Significant effect (DEFINE) ׇ (CONFIRM) | ✓21% reduction vs. placebo (DEFINE) × ‡ () | |
- | ✓ 24–42% reduction vs IFN-β-1a | ||
- | - | ✓ (ALLEGRO) 33% reduction vs placebo (BRAVO) 28–34% reduction vs placebo | |
Daclizumab [49] | ✓ | ✓ | - |
Significant effect (Week 0–24) 9% reduction vs IM IFN-β-1a | Significant effect (Week 24–96) 7% reduction vs IM IFN-β-1a | ||
✓ | ✓ | ✓ | |
23–40% reduction vs placebo | 28–45% reduction vs placebo | 33–35% reduction vs placebo | |
✓§ 45% reduction vs. IM IFN β-1a (TRANSFORMS) | - | - |